Dillon Cockrell, MD

307 posts

Dillon Cockrell, MD

Dillon Cockrell, MD

@DCockrellMD

Dad and husband | @DukeGUCancer GU Oncologist, DCI Center for Prostate and Urologic Cancers | Former @UNC Hem/Onc Chief Fellow | @vtcsom grad | Phase 1 trials

North Carolina Katılım Haziran 2023
328 Takip Edilen250 Takipçiler
Sabitlenmiş Tweet
Dillon Cockrell, MD
Dillon Cockrell, MD@DCockrellMD·
I recently spoke at the @KidneyCancer Association Duke/UNC patient event on #RCC treatment. We covered: • Adjuvant pembro for higher-risk pts • IO/TKI and dual IO strategies • How we personalize treatment • Role of clinical trials 📽️ Full talk: youtu.be/fSeaxjagqz4?si…
YouTube video
YouTube
English
2
0
4
832
Dillon Cockrell, MD retweetledi
Bruno Bastos MD
Bruno Bastos MD@BrunoBastosMD·
Our work showing concordance between clinical, genomic and AI based risk stratification in #prostatecancer @asco #GU26
Bruno Bastos MD tweet media
English
0
5
14
1.1K
Dillon Cockrell, MD
Dillon Cockrell, MD@DCockrellMD·
#LITESPARK022: Adjuvant #RCC phase III with pembro +/- belzutifan with first int analysis by @DrChoueiri. Improved DFS at 30 months (75 vs 68 %, HR 0.72). OS with HR 0.78 but immature. Tox with 52% vs 30% TrGr3+ AE with combo (anemia/hypoxia added). OS is important for adjuvant therapy but signal is there and DFS is meaningful as well. Pembro/bel should be an option for patients willing to accept higher chance of manageable toxicity. #GU26 @Daniel_J_George @OncoAlert @GUOncologyNow @KidneyCancer
English
1
4
12
1.1K
Dillon Cockrell, MD
Dillon Cockrell, MD@DCockrellMD·
#LITESPARK011: phase III of lenvatinib + belzutifan vs cabozantinib in advanced #ccRCC after IO. Len/bel improved PFS (14 v 10 mo, HR 0.70) and ORR (52% vs 40%). OS signal present (35 vs 27 mo, HR 0.80) for combo but immature. Duration of response was almost doubled (49% vs 25% at 2 yrs). Anemia/hypoxia main added tox. Belzutifan (HIF2a inhibitor) is the first major novel mechanistic drug in RCC since the IO/TKI era. Combo data here is practice changing for many. #GU26 @Daniel_J_George @KidneyCancer @OncoAlert @GUOncologyNow
Dillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet media
English
1
6
9
477
Dillon Cockrell, MD
Dillon Cockrell, MD@DCockrellMD·
#INDIBLADE: phase II bladder sparing trial for #MIBC with induction dual IO (ipi/nivo) followed by consolidation chemoRT. Met primary EFS with 76% intact bladder at 2 years. Early OS data but 96% alive at 2 years. Baseline and post-treatment #ctDNA remains predictive of outcomes, an ongoing theme in #BladderCancer. Expect we will need utDNA incorporated with similar non-surgical approaches for local recurrence monitoring in the future. #GU26 @OncoAlert @GUOncologyNow @urotoday
Dillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet media
English
1
5
11
688
Dillon Cockrell, MD
Dillon Cockrell, MD@DCockrellMD·
Great first day with important progress for #prostatecancer patients, podium talks from @Daniel_J_George and @AarmstrongDuke, and a peak into the future of cancer research from the #GU26 keynote. @DukeCancer @DukeGUCancer @oncodaily @OncoAlert @UrologyTimes @urotoday @ASCO @ASCOPost @PCFnews @GUOncologyNow
Dan George@Daniel_J_George

Highlights of #prostatecancer day at #GU26, including AI impacts on practicing-changing research and refreshed guidelines for clinical research @DukeCancer @DukeGUCancer @DCockrellMD

English
0
1
6
311
Dillon Cockrell, MD retweetledi
Dan George
Dan George@Daniel_J_George·
Congratulations on this to my colleague Chris Hoimes. @DukeGUCancer @DukeCancer
Dillon Cockrell, MD@DCockrellMD

Big day for #bladdercancer at #GU26 kicks off with much anticipated KNB15/EV304 trial for periop EV plus pembro vs neoadjuvant gem/cisplatin in MIBC. Significant improvements in both EFS and OS (HR 0.65) with pCR 55 vs 32% favoring EV-P. New SOC for #MIBC! Next questions: How much adjuvant therapy is truly needed? Can we spare surgery for carefully selected patients? ctDNA/utDNA may help answer in the coming years. @OncoAlert @OncLive @GUOncologyNow @MattGalsky @DrChrisHoimes @BladderCancerUS

English
0
4
18
1.5K
Dillon Cockrell, MD
Dillon Cockrell, MD@DCockrellMD·
#RETAIN: analysis of #ctDNA in two trials of #MIBC bladder preservation after cisplatin based chemo +/- nivolumab. RETAIN-2 (chemoIO) showed selected patients may safely undergo surveillance. Pooled ctDNA data was clearly predictive of outcomes regardless of surgery for systemic disease, but not able predict local control. Can utDNA fill this gap in patients who decline cystectomy? I expect ctDNA/utDNA will be the future of bladder cancer surveillance across all stages of disease. #GU26 @OncoAlert @GUOncologyNow @NateraGenetics
Dillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet media
English
0
2
9
1.4K
Dillon Cockrell, MD
Dillon Cockrell, MD@DCockrellMD·
Big day for #bladdercancer at #GU26 kicks off with much anticipated KNB15/EV304 trial for periop EV plus pembro vs neoadjuvant gem/cisplatin in MIBC. Significant improvements in both EFS and OS (HR 0.65) with pCR 55 vs 32% favoring EV-P. New SOC for #MIBC! Next questions: How much adjuvant therapy is truly needed? Can we spare surgery for carefully selected patients? ctDNA/utDNA may help answer in the coming years. @OncoAlert @OncLive @GUOncologyNow @MattGalsky @DrChrisHoimes @BladderCancerUS
Dillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet media
English
0
7
17
2K
Dillon Cockrell, MD
Dillon Cockrell, MD@DCockrellMD·
The #GUNS trial is an umbrella neoadjuvant study in high risk #prostatecancer with several tailored cohorts including triplet with ARPI/docetaxel. Interesting genomic response data from prostatectomy path, showing chemo activity signal for aggressive biology (TP53, PTEN, RB1, AKT). Suggests we’re on the right track with genomics influencing intensification in advanced disease. #GU26 @OncoAlert @urotoday @PCFnews
Dillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet media
English
0
6
12
841
Dillon Cockrell, MD
Dillon Cockrell, MD@DCockrellMD·
Multidisciplinary case discussion for #prostatecancer highlights practice changing utility of tools like @arteraAI prostate test in guiding ADT intensification in localized disease. A clinic-ready use case stemming from the keynote #AI discussion. The @arteraAI test increases confidence for me and the patient that he gets the right amount of treatment, sparing toxicity from some and improving cancer outcomes for others. #GU26 @urotoday @OncoAlert @OncLive @PCFnews @Larvol
Dillon Cockrell, MD tweet mediaDillon Cockrell, MD tweet media
English
0
6
8
447

Keşfet

@DukeRaleigh @DukeHealth @DukeCancer @urotoday @GUOncologyNow @DukeGUCancer @jitcancer @kgre23